Differential metabolites facilitate metabolic dysfunction-associated fatty liver disease malignancy via immune evasion and M2-polarized macrophages

Figure 1 Dynamic pathology and differentially expressed genes in the liver during metabolic dysfunction-associated fatty liver disease malignancy. A: Livers of Sprague-Dawley rats fed a high-fat diet plus 2-fluorenylacetamide; B: Liver grouping according to hematoxylin and eosin staining; C: Lipid analysis via Oil Red O staining; D: Enrichment analysis of differentially expressed genes associated with metabolic dysfunction-associated fatty liver disease malignancy; E: Lipid metabolism differentially expressed genes network. NC: Normal control; MAFLD: Metabolic dysfunction-associated fatty liver disease; MASH: Metabolic dysfunction-associated steatohepatitis; LC: Liver cirrhosis; HCC: Hepatocellular carcinoma; H&E: Hematoxylin and eosin.